Drug Type Small molecule drug |
Synonyms BKA-073 |
Target |
Action agonists |
Mechanism BAK agonists(BCL2 antagonist/killer 1 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC19H23N3O2 |
InChIKeyHTYURTLQTGVNJH-UHFFFAOYSA-N |
CAS Registry739309-23-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | Preclinical | United States | 01 Jan 2021 |